MoonLake Immunotherapeutics SEC filings MLTX
MoonLake Immunotherapeutics has 331 filings in SEC EDGAR's recent list, going back to Aug 28, 2020. Its latest annual report, Form ARS, was filed on Apr 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Sep 30, 2026 | Sep 30, 2026 |
| S-8 | Employee stock plan registration | Aug 10, 2026 | — |
| S-3ASR | Automatic shelf registration | Aug 10, 2026 | — |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Other events
|
Jul 15, 2026 | Jul 14, 2026 |
| 8-K |
Current report
Material agreement
|
Jun 25, 2026 | Jun 23, 2026 |
| 424B5 | Prospectus supplement | Jun 24, 2026 | — |
| 424B5 | Prospectus supplement | Jun 22, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 22, 2026 | Jun 21, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 9, 2026 | Jun 4, 2026 |
| 8-K |
Current report
Material agreement
|
Jun 1, 2026 | May 22, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 11, 2026 | May 10, 2026 |
| ARS | Annual report to shareholders | Apr 21, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 21, 2026 | — |
| DEF 14A | Proxy statement | Apr 21, 2026 | Jun 4, 2026 |
| 10-K | Annual report | Feb 25, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, Results of operations, New debt, Officer or director change, Regulation FD disclosure, Other events
|
Feb 23, 2026 | Feb 18, 2026 |
| 8-K |
Current report
Other events
|
Jan 8, 2026 | Jan 8, 2026 |
| 8-K |
Current report
Material agreement
|
Nov 5, 2025 | Nov 5, 2025 |
| 424B5 | Prospectus supplement | Nov 5, 2025 | — |
| 10-Q | Quarterly report | Nov 5, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 5, 2025 | Nov 5, 2025 |
| 8-K |
Current report
Other events
|
Sep 29, 2025 | Sep 29, 2025 |
| 10-Q | Quarterly report | Aug 5, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2025 | Aug 5, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 6, 2025 | Jun 5, 2025 |
| 10-Q | Quarterly report | May 12, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 12, 2025 | May 12, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 29, 2025 | Apr 29, 2025 |
| ARS | Annual report to shareholders | Apr 22, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 22, 2025 | — |
| DEF 14A | Proxy statement | Apr 22, 2025 | Jun 5, 2025 |
| 8-K |
Current report
Material agreement, New debt, Regulation FD disclosure
|
Apr 3, 2025 | Mar 31, 2025 |
| 10-K | Annual report | Feb 26, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 26, 2025 | Feb 26, 2025 |
| 8-K |
Current report
Officer or director change
|
Dec 18, 2024 | Dec 12, 2024 |
| 10-Q | Quarterly report | Nov 7, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 11, 2024 | Sep 11, 2024 |
| 10-Q | Quarterly report | Aug 7, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2024 | Aug 7, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 10, 2024 | Jun 10, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 6, 2024 | Jun 5, 2024 |
| UPLOAD | Letter from the SEC | May 13, 2024 | — |
| CORRESP | Letter to the SEC | May 7, 2024 | — |
| 10-Q | Quarterly report | May 7, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 7, 2024 | May 7, 2024 |
| 10-K/A | Amended annual report | May 7, 2024 | Dec 31, 2023 |
| UPLOAD | Letter from the SEC | Apr 29, 2024 | — |
| ARS | Annual report to shareholders | Apr 24, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 24, 2024 | — |
| DEF 14A | Proxy statement | Apr 24, 2024 | Jun 5, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 11, 2024 | Mar 10, 2024 |
| 10-K | Annual report | Feb 29, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Feb 29, 2024 | Feb 29, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 26, 2024 | Feb 26, 2024 |
| 10-Q | Quarterly report | Nov 14, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2023 | Nov 14, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 6, 2023 | Nov 5, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 16, 2023 | Oct 15, 2023 |
| EFFECT | Filing | Sep 11, 2023 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 11, 2023 | Sep 11, 2023 |
| CORRESP | Letter to the SEC | Sep 7, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 6, 2023 | — |
| 8-K |
Current report
Officer or director change
|
Sep 1, 2023 | Aug 30, 2023 |
| S-3 | Shelf registration | Aug 31, 2023 | — |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Material agreement, Other events
|
Jun 29, 2023 | Jun 27, 2023 |
| 424B5 | Prospectus supplement | Jun 29, 2023 | — |
| 424B3 | Prospectus | Jun 27, 2023 | — |
| 424B5 | Prospectus supplement | Jun 26, 2023 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 26, 2023 | Jun 26, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 7, 2023 | Jun 7, 2023 |
| 8-K |
Current report
Officer or director change
|
May 19, 2023 | May 15, 2023 |
| 424B5 | Prospectus supplement | May 11, 2023 | — |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| EFFECT | Filing | May 9, 2023 | — |
| CORRESP | Letter to the SEC | May 5, 2023 | — |
| EFFECT | Filing | May 4, 2023 | — |
| UPLOAD | Letter from the SEC | May 4, 2023 | — |
| S-3 | Shelf registration | May 1, 2023 | — |
| POS AM | Filing | May 1, 2023 | — |
| ARS | Annual report to shareholders | Apr 26, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 26, 2023 | — |
| DEF 14A | Proxy statement | Apr 26, 2023 | Jun 7, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 19, 2023 | Apr 19, 2023 |
| 424B3 | Prospectus | Mar 28, 2023 | — |
| EFFECT | Filing | Mar 27, 2023 | — |
| POS AM | Filing | Mar 20, 2023 | — |
| 10-K | Annual report | Mar 20, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 20, 2023 | Mar 20, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 10, 2023 | Mar 10, 2023 |
| 424B3 | Prospectus | Nov 14, 2022 | — |
| 10-Q | Quarterly report | Nov 14, 2022 | Sep 30, 2022 |
| S-8 | Employee stock plan registration | Sep 30, 2022 | — |
| 424B3 | Prospectus | Aug 12, 2022 | — |
| 10-Q | Quarterly report | Aug 12, 2022 | Jun 30, 2022 |
| EFFECT | Filing | Aug 2, 2022 | — |
| 424B3 | Prospectus | Aug 2, 2022 | — |
| CORRESP | Letter to the SEC | Jul 29, 2022 | — |
| CORRESP | Letter to the SEC | Jul 26, 2022 | — |
| S-1/A | Amended registration statement | Jul 26, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 21, 2022 | — |
| CORRESP | Letter to the SEC | Jul 15, 2022 | — |
| S-1/A | Amended registration statement | Jul 15, 2022 | — |
| 8-K |
Current report
Auditor change
|
Jun 17, 2022 | Jun 15, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 7, 2022 | Jun 7, 2022 |
| 8-K/A |
Amended current report
Acquisition or sale of assets
|
May 16, 2022 | Apr 5, 2022 |
| 10-Q | Quarterly report | May 16, 2022 | Mar 31, 2022 |
| UPLOAD | Letter from the SEC | May 16, 2022 | — |
| S-1/A | Amended registration statement | May 2, 2022 | — |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Apr 11, 2022 | Apr 5, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Mar 31, 2022 | Mar 31, 2022 |
| DEFA14A | Additional proxy material | Mar 25, 2022 | — |
| 425 | Current report | Mar 24, 2022 | — |
| 8-K |
Current report
New debt
|
Mar 24, 2022 | Mar 21, 2022 |
| DEFA14A | Additional proxy material | Mar 24, 2022 | — |
| S-1/A | Amended registration statement | Mar 14, 2022 | — |
| S-1/A | Amended registration statement | Mar 8, 2022 | — |
| DEFR14A | Proxy statement | Mar 4, 2022 | — |
| DEFA14A | Additional proxy material | Feb 25, 2022 | — |
| 8-K |
Current report
Material agreement
|
Feb 25, 2022 | Feb 20, 2022 |
| 10-K | Annual report | Feb 17, 2022 | Dec 31, 2021 |
| DEFM14A | Definitive proxy statement | Feb 14, 2022 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2022 | — |
| CORRESP | Letter to the SEC | Feb 11, 2022 | — |
| PRER14A | Preliminary revised proxy materials | Feb 11, 2022 | — |
| S-1 | Registration statement | Feb 11, 2022 | — |
| UPLOAD | Letter from the SEC | Feb 10, 2022 | — |
| CORRESP | Letter to the SEC | Feb 3, 2022 | — |
| PRER14A | Proxy statement | Feb 3, 2022 | — |
| UPLOAD | Letter from the SEC | Feb 2, 2022 | — |
| PRER14A | Proxy statement | Jan 21, 2022 | — |
| CORRESP | Letter to the SEC | Jan 20, 2022 | — |
| DEFA14A | Additional proxy material | Jan 19, 2022 | — |
| UPLOAD | Letter from the SEC | Jan 12, 2022 | — |
| UPLOAD | Letter from the SEC | Jan 12, 2022 | — |
| PRER14A | Proxy statement | Dec 16, 2021 | — |
| CORRESP | Letter to the SEC | Dec 15, 2021 | — |
| CORRESP | Letter to the SEC | Dec 14, 2021 | — |
| 10-Q/A | Amended quarterly report | Dec 14, 2021 | Sep 30, 2021 |
| 10-K/A | Amended annual report | Dec 14, 2021 | Dec 31, 2020 |
| 8-K |
Current report
Restatement
|
Dec 3, 2021 | Nov 30, 2021 |
| UPLOAD | Letter from the SEC | Nov 24, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 24, 2021 | — |
| 10-Q | Quarterly report | Nov 12, 2021 | Sep 30, 2021 |
| PREM14A | Proxy statement | Oct 29, 2021 | Oct 29, 2021 |
| DEFA14A | Additional proxy material | Oct 28, 2021 | — |
| DEFA14A | Additional proxy material | Oct 4, 2021 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Oct 4, 2021 | Oct 4, 2021 |
| 10-Q | Quarterly report | Aug 16, 2021 | Jun 30, 2021 |
| 10-Q | Quarterly report | May 21, 2021 | Mar 31, 2021 |
| NT 10-Q | Notification of late filing | May 18, 2021 | Mar 31, 2021 |
| 8-K |
Current report
Officer or director change
|
May 3, 2021 | Apr 27, 2021 |
| 10-K | Annual report | Mar 31, 2021 | Dec 31, 2020 |
| 10-Q | Quarterly report | Dec 3, 2020 | Sep 30, 2020 |
| 8-K |
Current report
Other events
|
Oct 28, 2020 | Oct 22, 2020 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Other events
|
Oct 22, 2020 | Oct 19, 2020 |
| 424B4 | Prospectus | Oct 21, 2020 | — |
| CERT | Filing | Oct 20, 2020 | — |
| EFFECT | Filing | Oct 19, 2020 | — |
| 8-A12B | For registration of certain classes | Oct 19, 2020 | — |
| S-1/A | Amended registration statement | Oct 16, 2020 | — |
| CORRESP | Letter to the SEC | Oct 15, 2020 | — |
| CORRESP | Letter to the SEC | Oct 15, 2020 | — |
| S-1/A | Amended registration statement | Oct 14, 2020 | — |
| CORRESP | Letter to the SEC | Oct 1, 2020 | — |
| S-1 | Registration statement | Oct 1, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 24, 2020 | — |
| DRS | Filing | Aug 28, 2020 | — |
Showing 175 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MLTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Zug, Switzerland
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1821586
- Former names
- Helix Acquisition Corp (until Mar 31, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.